Mayo Clinic Proceedings Home

Relationship of Body Mass Index With Outcomes After Transcatheter Aortic Valve Replacement: Results From the National Cardiovascular Data–STS/ACC TVT Registry



      To investigate the relationship of body mass index (BMI) with short- and long-term outcomes after transcatheter aortic valve replacement (TAVR).

      Patients and Methods

      The relationship between BMI and baseline characteristics and procedural characteristics was assessed for 31,929 patients who underwent TAVR between November 1, 2011, and March 31, 2015, from the STS/ACC TVT Registry. Registry data on 20,429 patients were linked to the Centers for Medicare and Medicaid Services to assess the association of BMI with 30-day and 1-year mortality using multivariable Cox proportional hazards models. The effect of BMI on mortality was also assessed with BMI as a continuous variable. Restricted cubic regression splines were used to model the effect of BMI and to determine appropriate cut points of BMI.


      Among 31,929 patients, 806 (2.5%) were underweight (BMI, <18.5 kg/m2), 10,755 (33.7%) had normal weight (BMI, 18.5- 24.9 kg/m2), 10,691 (33.5%) were overweight (BMI, 25.0-29.9 kg/m2), 5582 (17.5%) had class I obesity (BMI, 30.0-34.9 kg/m2), 2363 (7.4%) had class II obesity (BMI, 35.0-39.9 kg/m2), and 1732 (5.4%) had class III obesity (BMI, ≥40 kg/m2). Patients in various BMI categories were different in most baseline and procedural characteristics. On multivariable analysis, compared with normal-weight patients, underweight patients had higher mortality at 30 days and at 1 year after TAVR (hazard ratio [HR], 1.35; 95% CI, 1.02-1.78 and HR, 1.41; 95% CI, 1.17-1.69, respectively), whereas overweight patients and those with class I and II obesity had a decreased risk of mortality at 1 year (HR, 0.88; 95% CI, 0.81-0.95, HR, 0.80; 95% CI, 0.72-0.89, and HR, 0.84; 95% CI, 0.72-0.98, respectively). For BMI of 30 kg/m2 or less, each 1-kg/m2 increase was associated with a 2% and 4% decrease in the risk of 30-day and 1-year mortality, respectively; for BMI greater than 30 kg/m2, a 1-kg/m2 increase was associated with a 3% increased risk of 30-day mortality but not with 1-year mortality.


      Results of this large registry study evaluating the relationship of BMI and outcomes after TAVR support the existence of an obesity paradox among patients with severe aortic stenosis undergoing TAVR.

      Abbreviations and Acronyms:

      ACC (American College of Cardiology), AR (aortic regurgitation), AS (aortic stenosis), BMI (body mass index), CMS (Centers for Medicare and Medicaid Services), CVD (cardiovascular disease), HF (heart failure), HR (hazard ratio), ICD-9 (International Classification of Diseases, Ninth Revision), IQR (interquartile range), IRB (institutional review board), MI (myocardial infarction), SAVR (surgical aortic valve replacement), STS (Society of Thoracic Surgeons), TAVR (transcatheter aortic valve replacement), TVT (Transcatheter Valve Therapy)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Osnabrugge R.L.
        • Mylotte D.
        • Head S.J.
        • et al.
        Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement; a meta-analysis and modeling study.
        J Am Coll Cardiol. 2013; 62: 1002-1012
        • Maluenda G.
        • Dvir D.
        Expanding indications for transcatheter aortic valve replacement.
        Expert Rev Cardiovasc Ther. 2014; 12: 693-702
        • Smith II, R.L.
        • Herbert M.A.
        • Dewey T.M.
        • et al.
        Does body mass index affect outcomes for aortic valve replacement surgery for aortic stenosis?.
        Ann Thorac Surg. 2012; 93: 742-746
        • Kappetein A.P.
        • Head S.J.
        • Généreux P.
        • et al.
        Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.
        J Am Coll Cardiol. 2012; 60: 1438-1454
        • van der Boon R.M.
        • Chieffo A.
        • Dumonteil N.
        • et al.
        • PRAGMATIC-Plus Researchers
        Effect of body mass index on short- and long-term outcomes after transcatheter aortic valve implantation.
        Am J Cardiol. 2013; 111: 231-236
        • Yamamoto M.
        • Hayashida K.
        • Watanabe Y.
        • et al.
        Effect of body mass index <20 kg/m2 on events in patients who underwent transcatheter aortic valve replacement.
        Am J Cardiol. 2015; 115: 227-233
        • Carroll J.D.
        • Edwards F.H.
        • Marinac-Dabic D.
        • et al.
        The STS-ACC transcatheter valve therapy national registry: a new partnership and infrastructure for the introduction and surveillance of medical devices and therapies.
        J Am Coll Cardiol. 2013; 62: 1026-1034
        • Holmes Jr., D.R.
        • Brennan J.M.
        • Rumsfeld J.S.
        • et al.
        • STS/ACC TVT Registry
        Clinical outcomes at 1 year following transcatheter aortic valve replacement.
        JAMA. 2015; 313: 1019-1028
        • National Heart Lung
        • Blood Institute Expert Panel
        Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report.
        Obes Res. 1998; 6 ([published correction appears in Obes Res. 1998;6(6):464]): 51S-209S
        • Leon M.B.
        • Piazza N.
        • Nikolsky E.
        • et al.
        Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium.
        J Am Coll Cardiol. 2011; 57: 253-269
        • Kappetein A.P.
        • Head S.J.
        • Généreux P.
        • et al.
        • Valve Academic Research Consortium-2
        Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.
        J Thorac Cardiovasc Surg. 2013; 145: 6-23
        • Fine J.P.
        • Gray R.J.
        A proportional hazards model for the subdistribution of a competing risk.
        J Am Stat Assoc. 1999; 94: 496-509
        • Lavie C.J.
        • Laddu D.
        • Arena R.
        • Ortega F.B.
        • Alpert M.A.
        • Kushner R.F.
        Healthy weight and obesity prevention: JACC Health Promotion Series.
        J Am Coll Cardiol. 2018; 72: 1506-1531
        • Elagizi A.
        • Kachur S.
        • Lavie C.J.
        • et al.
        An overview and update on obesity and the obesity paradox in cardiovascular diseases.
        Prog Cardiovasc Dis. 2018; 61: 142-150
        • Sharma A.
        • Lavie C.J.
        • Borer J.S.
        • et al.
        Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure.
        Am J Cardiol. 2015; 115: 1428-1434
        • Kodali S.K.
        • Williams M.R.
        • Smith C.R.
        • et al.
        • PARTNER Trial Investigators
        Two-year outcomes after transcatheter or surgical aortic-valve replacement.
        N Engl J Med. 2012; 366: 1686-1695
        • Alfredsson J.
        • Stebbins A.
        • Brennan J.M.
        • et al.
        Gait speed predicts 30-day mortality after transcatheter aortic valve replacement: results from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.
        Circulation. 2016; 133: 1351-1359
        • Carbone S.
        • Lavie C.J.
        • Arena R.
        Obesity and heart failure: focus on the obesity paradox.
        Mayo Clin Proc. 2017; 92: 266-279
        • McAuley P.A.
        • Keteyian S.J.
        • Brawner C.A.
        • et al.
        Exercise capacity and the obesity paradox in heart failure: the FIT (Henry Ford Exercise Testing) Project.
        Mayo Clin Proc. 2018; 93: 701-708
        • Ventura H.O.
        • Carbone S.
        • Lavie C.J.
        Muscling up to improve heart failure prognosis [editorial].
        Eur J Heart Fail. 2018; 20: 1588-1590
        • Carbone S.
        • Billingsley H.E.
        • Rodriguez-Miguelez P.
        • et al.
        Lean mass abnormalities in heart failure: the role of sarcopenia, sarcopenic obesity, and cachexia [published online ahead of print March 28, 2019].
        (Curr Probl Cardiol)
        • Zavin A.
        • Daniels K.
        • Arena R.
        • et al.
        Adiposity facilitates increased strength capacity in heart failure patients with reduced ejection fraction.
        Int J Cardiol. 2013; 167: 2468-2471
        • Ortega F.B.
        • Sui X.
        • Lavie C.J.
        • Blair S.N.
        Body mass index, the most widely used but also widely criticized index: would a criterion standard measure of total body fat be a better predictor of cardiovascular disease mortality.
        Mayo Clin Proc. 2016; 91: 443-455
        • Carbone S.
        • Elagizi A.
        • Lavie C.J.
        Obesity and mortality risk in heart failure: when adipose tissue distribution matters [editorial].
        Eur J Heart Fail. 2018; 20: 1278-1280
        • Stokes A.
        • Preston S.H.
        Revealing the burden of obesity using weight histories.
        Proc Natl Acad Sci U S A. 2016; 113: 572-577

      Linked Article